The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Practical Approach for Gliomas, Part 2. Isocitrate Dehydrogenase Status - Imaging Correlation

Arevalo, O.J.; Valenzuela, R.; Esquenazi, Y.; Rao, M.; Tran, B.; Zhu, J.; Bhattacharjee, M.; Doyle, N.; Riascos, R.F.

View Article on Neurographics Website

Date of Activity Release: Oct. 1, 2017
Date of Activity Expiration: Oct. 1, 2020

Target Audience:
Intended for neuroradiologists and neuroradiology trainees with varying degrees of experience.

Learning Objective:
Describe the main MR findings in differentiating gliomas isocitrate dehydrogenase mutant versus isocitrate dehydrogenase wild type.

Central nervous system glial tumors are now classified based on their histologic appearance and their isocitrate dehydrogenase status. The last World Health Organization classification update, published in 2016, gives more importance to the genotype as a determinant of prognosis than to the histologic phenotype. The main difficulty is that the genetic study considered as the criterion standard can only be done after surgical intervention, once the tissue is available. This new approach brings a new challenge to radiologists, that is, to identify imaging features that lead to a given genotype at the initial diagnosis. This article reviewed the state of the art in the correlation between imaging and isocitrate dehydrogenase status, and provided representative illustrations.

Commercial Support
No commercial support was received for this activity.

Credit Designation Statement

The American Society of Neuroradiology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Neuroradiology designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Physician Participation:
Each participant will review the corresponding Neurographics article located at Upon completion, each physician will complete and pass a post-test with a score of at least 80% to receive a CME certificate.

All individuals in control of content have disclosed the following relevant financial relationships. All of these relationships were treated as a conflict of interest, and have been resolved (C7 SCS 6.1-6.2, 6.5)

Authors have no relevant financial relationships.





Barton Branstetter 

Editor in Chief

None, N/A

Adam Flanders

Deputy Editor

Royalties, Lippincott Williams and Wilkins

Robert Quencer 

Consulting Editor

None, N/A

Mark Mullins

Associate Editor

Non-remunerative position, AUR6

Meng Law

Associate Editor

Stockholder, Clinical Imaging

Michele Johnson

Associate Editor

Consultant, Boston Scientific, Inc.

Edward Escott

Associate Editor

Grant, Atherysys, Inc.; Royalties, Thieme Medical Publishers

Scott Faro

Associate Editor

None, N/A

Tina Young Poussaint

Associate Editor

None, N/A

Dheeraj Ghandi

Associate Editor

Grant, Arstasis, Axera Inc.; Consultant, Covidien, EV3

Contact Information:
If you have questions regarding this enduring material activity, please contact us at

Privacy Policy and Confidentiality Policy:
The ASNR does not share your personal information provided to this site with any third party, except where required by CME governing bodies for verification of CME activities. Your email address will only be used to contact you in relation to your activities on the website, except where you have given ASNR permission to contact you with additional information. ASNR adheres to the same policy for members as nonmembers, except that: ASNR member mailing address information may be shared with providers of accredited CME activities.

Copyright © American Society of Neuroradiology, 2011-2017